Kornimate/medical-research-clean huggingface dataset:
effects of pain, disability and cervicokinesthesia after cervical manipulation

Conditions: Neck Pain

Summary: cervical spine manipulation has been found to be effective in patients with mechanical neck pain. discrepancies exist on the side of manipulation and the placebo effect of this manual intervention. in addition, some authors have proposed that spinal manipulation can alter proprioception of the cervical spine. the aim of this study will be to investigate the effects of cervical spine manipulation on pain, disability, widespread pressure pain sensitivity, and cervicokinethesia in patients with mechanical neck pain.

cervical spine manipulation has been found to be effective in patients with mechanical neck pain. discrepancies exist on the side of manipulation and the placebo effect of this manual intervention. in addition, some authors have proposed that spinal manipulation can alter proprioception of the cervical spine. the aim of this study will be to investigate the effects of cervical spine manipulation on pain, disability and cervicokinethesia in patients with mechanical neck pain. patients will receive cervical spine manipulation in either right or left side of the neck and will be assessed on pain intensity, neck-related disability, widespread pressure pain sensitivity, and cervicokinethesia by an assessor blinded to the allocation group.

Eligibility criteria:
inclusion criteria: - generalized neck-shoulder pain with symptoms provoked by neck postures, neck movement, or palpation of the cervical musculature. exclusion criteria: * any contraindication to manipulation, e.g., positive extension-rotation test; * whiplash injury; * previous cervical surgery; * cervical radiculopathy or myelopathy; * diagnosis of fibromyalgia syndrome; * having undergone spinal manipulative therapy in the previous 6 months; * less than 18 or greater than 65 years of age.

Keywords: cervical spine spinal manipulation
pharmaceutical consultation at hospital discharge and adherence to anti-infective treatment

Conditions: Infection

Summary: the main objective of this study is to evaluate the impact of a pharmaceutical consultation at the time of hospital discharge on the adherence of patients ; non-adherence is determined by the following criteria: as concerns prescribed anti-infectious treatments, at least one of the following 4 criteria is true: 1. . the patient did not go and get his/her treatment at the pharmacy; 2. . the number of treatment units dispensed by the pharmacy is \< the number of treatment units prescribed; 3. . the patient stopped taking a treatment before the recommended time, or continued taking a treatment after the recommended time; 4. . the number of treatment units taken by the patient (self-declaration) is \ to the number of units prescribed.

the secondary objectives of this study are : a- to assess the percentage of patients who obtained their anti- infective pharmaceuticals b- to evaluate the ratio of the number of units of anti- infective drugs dispensed by the pharmacy over the number of units of anti- infective drugs prescribed c- to determine the ratio of the number of premature discontinuations of anti -infective treatments over the number of lines of anti -infective treatments prescribed d- evaluate the ratio of the number of units actually taken by the patient (based on a self-declaration) over the number of units of anti- infective drugs prescribed e- to measure the comprehension concerning anti- infective treatments after returning home (based on a quiz) f- to determine the risk factors for non- adherence to anti- infective therapy based on the characteristics of the study population g- assess patient satisfaction concerning a pharmaceutical consultation at hospital discharge (questionnaire) h- assess the impact of a pharmaceutical consultation on primary non-adherence (criteria 1 and 2) and secondary non- adherence (criteria 3 and 4)

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is hospitalized in the infectious and tropical diseases department of the nîmes university hospital, and is scheduled for hospital discharge with one or more pharmaceutical prescriptions for anti-infectious treatments exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient resides in a care establishment, or has home medical/nursing service * the patient is suffering from chronic infection (\>4 weeks of treatment required) * the patient is suffering from handicapping deafness, dementia, or does not have a telephone * intravenous, intramuscular or subcutaneous anti-infectious treatments are prescribed * prescription of antiretroviral treatments

Keywords: anti-infectious treatment observance pharmaceutical consultation
time restricted feeding on nonalcoholic fatty liver disease ( treaty-fld )：a 12-month follow-up study

Conditions: Nonalcoholic Fatty Liver Disease

Summary: time restricted feeding (trf) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. this is a 6-month follow-up study of treaty-fld trial to evaluate the effect of time restricted feeding (trf) on hepatic fat contents and cardiometabolic risk factors in obese adults over 6 months compared to continuous energy restriction (cer).


Eligibility criteria:
inclusion criteria: 1. man or women aged≥18 years; 2. subjects with nafld determined by mri (intrahepatic triglyceride content ≥5%); 3. body mass index (bmi)of 28.0 to 45.0 kg/m2; exclusion criteria: 1. history of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, cirrhosis, and liver cancer; 2. history of hiv, or active pulmonary tuberculosis; 3. diagnosis of type 1 and type 2 diabetes; 4. history of malignant tumors; 5. serious liver dysfunction or chronic kidney disease (ast or alt \> 3 times the upper limit of normal, or egfr\<30 ml/min/1.73 m2); 6. significant alcohol consumption in the past six months (consumed more than 20 g/day for women or 30 g/day for men); 7. history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months; 8. history of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months; 9. history of cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity; 10. being a smoker or having been a smoker in the 3 months prior to their screening visit; 11. taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician; 12. currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ; 13. women who are pregnant or plan to become pregnant; 14. patients who cannot be followed for 24 months (due to a health situation or migration); 15. patients who are unwilling or unable to give informed consent.

Keywords: nonalcoholic fatty liver disease time restricted feeding calorie restriction
stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery

Conditions: Recurrent Renal Cell Cancer; Stage IV Renal Cell Cancer

Summary: this pilot clinical trial studies stereotactic body radiation therapy in treating patients with metastatic kidney cancer undergoing surgery. stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

primary objectives: i. assess the impact of stereotactic body radiation therapy (sbrt) on the immune system in patients with metastatic renal cell carcinoma (rcc). secondary objectives: i. assess changes in immune parameters prior to radiation, post radiation and post nephrectomy. tertiary objectives: i. assess surgical parameters for partial or radical nephrectomy post sbrt. outline: patients undergo sbrt on day 1 and undergo partial or radical nephrectomy on day 29. after completion of study treatment, patients are followed up at 30 days.

Eligibility criteria:
inclusion criteria: * have metastatic rcc with primary tumor in place * must be surgical candidates as deemed fit by surgeon * have measurable disease per response evaluation criteria in solid tumors (recist) 1.1 criteria present * patients of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * patient or legal representative must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure exclusion criteria: * patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin c) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * radiation to primary tumor prior to enrollment in this study * pregnant or nursing female patients * unwilling or unable to follow protocol requirements * any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive treatment * received an investigational agent within 30 days prior to enrollment
the development and health of the intestinal flora during the first year of life

Conditions: Healthy; Microbial Colonization

Summary: in this research study (prevent 1), alba health, in collaboration with academic institutions (uppsala university, copsac and university of antwerp) is investigating the association between the developing gut microbiota (collection of microbes present in the human gut) in the first year of life and lifestyle, wellbeing and health in a swedish population. the study is the first of its kind in a swedish population to collect and associate microbiome composition to an extensive family history and health questionnaire, stool colour and crying type, building on learnings from previous studies performed in other countries, such as the helmi and copsac studies (helmi - finnish health and early life microbiota cohort from the university of helsinki in finland; copsac - copenhagen prospective studies on asthma in childhood in denmark). the prevent 1 study is an observational research study led by alba health involving 300 families in sweden with children between 0 and 12 months of age at the time of the study's start. after providing informed consent, the participating families will be asked to provide three stool samples from their child (the sample collection is not invasive and does not cause discomfort) and will be asked to answer questionnaires on lifestyle, well-being and family health. the participating families will not be asked to change their lifestyle beyond sample and data collection. from the collected stool samples, we will extract microbial dna and subject this to deep metagenomic sequence analysis. the study will only analyze microbial dna, any human related material will be discarded. the stool samples will be destroyed within one month of sequencing (maximum 3 months from collection). the data will be stored according to gdpr and swedish law, with informed consent in sweden and with appropriate security measures. all research will be carried out in sweden.


Eligibility criteria:
inclusion criteria: * healthy infants, no preterm and not undergoing antibiotic treatment exclusion criteria: * preterm delivered infants or infants undergoing antibiotic treatment

Keywords: microbiome, infant, healthy
a study of transcranial direct current stimulation (tdcs) to treat depression

Conditions: Depressive Disorder, Major; Bipolar Disorder

Summary: depression is a common illness with an approximate lifetime prevalence of 17 %, conferring a large burden of disease in the community, often due to inadequate treatment. thus there is interest in the therapeutic potential of non invasive, novel forms of brain stimulation, such as transcranial direct current stimulation (tdcs). two small studies have been published in the last two years indicating that 20 minutes of either 1 or 2ma tdcs over 5 or 10 sessions is safe, painless and well tolerated. the investigators' own pilot data (n=30) also suggests the technique has antidepressant effects and is safe (5-10 sessions of tdcs at 1 ma). this study will extend previous findings, testing a more definitive tdcs approach (also left prefrontal anodal stimulation) with a longer treatment course (15 sessions), at 2 ma (which has been found to be safe and more effective than 1 ma in cognitive studies), and in a larger sample (n=68), using a placebo-controlled design. it is hypothesised that active tdcs (15 sessions) will have greater efficacy than sham treatment (15 sessions) in reducing the severity of depressive symptoms in patients in an episode of major depression. a second hypothesis is that 15 sessions of tdcs will not cause any significant adverse effects or cause decline in neuropsychological functioning in comparison to a sham control.


Eligibility criteria:
inclusion criteria: * meets criteria for dsm-iv major depressive episode exclusion criteria: * diagnosis (as defined by dsm-iv) of: any psychotic disorder except bipolar disorder(lifetime); eating disorder (current or within the past year); obsessive compulsive disorder (lifetime); post-traumatic stress disorder (current or within the past year); mental retardation. * history of drug or alcohol abuse or dependence (as per dsm-iv criteria) within the last 3 months (except nicotine and caffeine). * inadequate response to ect in the current episode of depression. * subject is on regular benzodiazepine medication which it is not clinically appropriate to discontinue. * subject requires a rapid clinical response due to inanition, psychosis or high suicide risk. * neurological disorder or insult, eg recent stroke (cva), which places subject at risk of seizure or neuronal damage with tdcs. * subject has metal in the cranium, skull defects, or skin lesions on scalp (cuts, abrasions, rash) at proposed electrode sites. * female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception

Keywords: depression treatment transcranial direct current stimulation
cyp4a11 and cyp4f2 gene variants as makers of cardiovascular adverse events of non-steroidal anti-inflammatory drugs

Conditions: Drug-Related Side Effects and Adverse Reactions

Summary: randomized, double-blinded, cross-over and placebo controlled clinical trial to evaluate the association between genetic polymorphism of cyp4f2 with cardiovascular adverse effects of non-steroidal anti-inflammatory drugs (nsaids). two groups were included according the cyp4f2 v433m genetic polymorphism (control - mm, n=7 vs. vv or vm variants, n=13). according the sample size planned, a mean difference of total body water delta between groups (control vs. polymorphic) of at least allow 10% could be observed.


Eligibility criteria:
inclusion criteria: healthy volunteers 18-65 years-old - exclusion criteria: use of drugs and without clinical history of adverse effects of nsaids -
risk factors of sternal wound infection after coronary artery bypass graft

Conditions: Coronary Artery Bypass Graft; Median Sternotomy

Summary: the investigators are trying to evaluate the performance of neutrophil and lymphocyte counts as a risk factor of deep sternal wound infection after coronary artery bypass graft surgery.

deep sternal wound infection after coronary artery bypass graft is a very dangerous complication as it prolongs hospital stay, increase morbidity and mortality, and increase cost of care. as a risk factor of surgical site infection, risk index reported by nnis (national nosocomial infection surveillance), euroscore, or society of thoracic surgeon risk score are currently used. however, as various performances are reported regarding these index or scoring systems, and many factors are needed for these index or scoring system, there is a need to develop a more simple risk factor with better performance. we focused on the differential blood cell count, as the neutrophil and lymphocyte count are related to the degree of surgical invasion, and inflammatory response. previous studies reported that the neutrophilia or lymphopenia is related to postoperative infection. therefore, we are trying to evaluate the performance of preoperative or postoperative the blood cell differential count as a risk factor for sternal wound infection after coronary artery bypass surgery.

Eligibility criteria:
inclusion criteria: * those underwent coronary artery bypass graft surgery with median sternotomy in samsung medical center during the period of january 2008 and december 2011. exclusion criteria: * those underwent coronary artery bypass graft surgery with mini-thoracotomy * those with insufficient study data recognized by electronic medical record

Keywords: sternal wound infection coronary artery bypass graft risk factor
intratumoral can2109 in subjects with solid tumors

Conditions: Solid Tumor; Lymphoma

Summary: a phase 1, dose escalation, open-label study of intratumoral can2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.

the scope of the study is to evaluate the safety of can2109 in humans, explore its safety, efficacy and collect data on the pharmacokinetics, as well as on the pharmacodynamic effect of the drug on the immune system locally and systemically, and on tumor markers.

Eligibility criteria:
inclusion criteria: 1. able and willing to provide written informed consent and willing to comply with the study's requirements. 2. male or female age ≥ 18 years at screening. 3. metastatic or locally advanced solid tumor that has progressed on, is refractory to, or for which there is no efficacious standard of care therapy. preferred tumor types include the following: a. carcinoma of skin, melanoma, merkel cell carcinoma (mcc), breast cancer, head and neck squamous cell carcinoma (hnscc), sarcoma, cervical carcinoma, and colorectal cancer 4. performance status of 0-1 on the ecog performance scale. exclusion criteria: 1. unresolved toxicities from prior therapy, defined as having not resolved to common terminology criteria for adverse events (ctcae) version 5.0 (v5.0) grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo. 2. treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent. 3. has an active infection requiring systemic therapy. 4. unstable/inadequate cardiac function defined as follows: 1. new york heart association class 3 or 4 congestive heart failure 2. uncontrolled hypertension 3. acute coronary syndrome within 6 months 4. clinical important cardiac arrhythmia 5. mean corrected qt (qtc) interval corrected for heart rate \> 480 ms. 5. a history of interstitial lung disease. 6. a history of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders. 7. participated in a clinical study of an investigational agent within 30 days of screening. 8. has known psychiatric, substance abuse, or other disorders that would interfere with cooperation with the requirements of the study in the opinion of the investigator. 9. is pregnant or breastfeeding.
bowel function and associated risk factors for bowel dysfunciton in patients with anorectal malformation

Conditions: Bowel Dysfunction

Summary: the present study was designed to evaluate bowel function in preschool and early childhood in a large number of patients with anorectal malformation and to identify the associated risk factors for bowel dysfunction.

anorectal malformation (arm) is a type of congenital malformation resulting from post-embryonic intestinal dysgenesis, occurring in about 1 in 5000 cases.surgery is an effective means of treating arm,which includes reconstruction of the anus and treatment of associated deformities. however, even with reconstruction of the anus, most children still have serious complications, such as constipation, fecal incontinence, urinary incontinence, and sexual dysfunction, in the mid-to-long postoperative period.a lot of studies have been designed to explore the trend toward normal bowel habits from preschool and early childhood age to adolescence or adult; however, no apparent improvement in bowel habits was completely confirmed. in contrast, many reports have shown that poor bowel function in preschool and early childhood may lead to social problems and depression in adolescence and adult.the reasons for bowel dysfunction of arm in preschool and early childhood were complicated and undefined,including associated malformations, the type of arm, and the development of the perianal sphincter,etc.the bowel function score (bfs) is currently used to assess mid- and long-term anal function in patients with arm, and comprises seven major categories (e.g., self-perception, fecal control, stool collection, and social problems) with a total of 20 points, or less than 17 points, for the presence of anal weakness (11-17 points, for the general weakness, or less than 11 points, for the severe weakness) .therefore,bowel function at preschool and early childhood should be evaluated in a large number of patients with arm and the associated risk factors for bowel dysfunction should also be assessed. the present study was designed to evaluate bowel function in preschool and early childhood in a large number of patients with arm and to identify the associated risk factors for bowel dysfunction using bfs.

Eligibility criteria:
inclusion criteria: anorectal malformation \>4 years old exclusion criteria: down syndrome patients \<4 years

Keywords: anorectal malformation bowel function risk factors